Emmaus Life Sciences, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

SELECTED FINANCIAL STATEMENT LIABILITIES (Tables)

12 Months Ended

Dec. 31, 2024

Accounts payable and accrued expenses as of December 31, 2024 and 2023 consisted of the following (in thousands):


	As of December 31,
	2024		2023
Accounts payable:
Clinical and regulatory expenses	$	452	$	696
Professional fees		904		721
Selling expenses		1,553		1,498
Manufacturing costs		706		914
Non-employee director compensation		966		766
Other vendors		594		518
Total accounts payable		5,175		5,113
Accrued interest payable, related parties		1,145		542
Accrued interest payable		2,874		3,122
Accrued expenses:
Payroll expenses		323		1,270
Government rebates and other rebates		7,229		5,881
Due to customers		15		844
Other accrued expenses		165		179
Total accrued expenses		7,732		8,174
Total accounts payable and accrued expenses	$	16,926		16,951

Other current liabilities consisted of the following (in thousands):


	As of December 31
	2024		2023
Trade discount	$	5,000	$	3,000
Unearned revenue (a)		10,000		10,000
Other current liabilities		1,557		1,681
Total other current liabilities	$	16,557	$	14,681

(a) Refer Note 3 for information regarding to the unearned revenue.

Other long-term liabilities consisted of the following (in thousands):


	As of December 31
	2024		2023
Trade discount	$	13,421	$	17,324
Other long-term liabilities		44		39
Total other long-term liabilities	$	13,465	$	17,363